Matinas BioPharma Holdings, Inc. (MTNB) is an innovative biopharmaceutical company dedicated to the development and commercialization of next-generation therapeutics to advance the standard of care. The company's vision is built around the discovery and development of products that support the health and wellness of patients around the globe. Matinas BioPharma Holdings, Inc. is publicly traded on the NYSE American under the ticker "MTNB."
This clinical-stage company is working tirelessly to create a robust portfolio of products, focusing on critical areas requiring unmet medical needs, such as cardiovascular and metabolic conditions. Their development efforts concentrate on utilizing their proprietary lipid nanocrystal (LNC) platform delivery technology. This technology enables a more effective delivery of drugs, including those that are water-insoluble due to their monolithic structure. Leveraging this proprietary LNC technology, Matinas BioPharma has made significant strides in drug delivery, absorption, and efficacy.
One of the company's leading projects is the development of MAT9001, a prescription-only omega-3 fatty acid-based composition, currently under investigation for potential benefits in treating cardiovascular and metabolic conditions. This differentiated product has shown promise across multiple identifiers vital to cardiovascular health and is positioned as a direct threat to established drugs in the marketplace.
Furthermore, the company is also exploring gene therapy and vaccination spaces, using its LNC platform to develop potentially life-altering solutions. Most notable is its MAT2203, an orally administered, encochleated formulation of amphotericin B, intended to treat systemic fungal infections and prevent such infections in patients with compromised immune systems. Through innovative applications of their technology, the company aims to revolutionize treatment methods, bringing forth lesser side-effects, and increased efficiency.
With its dynamic leadership team, and a scientific advisory board of renowned key opinion leader, Matinas BioPharma Holdings Inc. is paving the way for groundbreaking advancements in the healthcare sector. By focusing its efforts on innovative technology and cutting-edge research, the company is steadily making a name for itself in the biopharmaceutical industry and working towards a healthier future for all.